Please provide your email address to receive an email when new articles are posted on . Researchers observed responses at all dose levels, with the recommended phase 2 regimen linked to durable ...

Data from the MajesTEC-1 trial shows that patients with relapsed/refractory multiple myeloma responded to Tecvalyi for a median of two years and lived without disease progression for nearly a year.

When we turn our attention to emerging global threats, we know what to expect: grim statistics, dire predictions, and—perhaps worst of all—disturbing revelations that no preventive or corrective ...

An estimated 2.8 million people worldwide have multiple sclerosis (MS). This autoimmune condition is the result of the immune system damaging parts of the nerves in the brain and spinal cord, which ...

“Patients did great” with a four-drug regimen for multiple myeloma, an expert told CURE®. Patients with newly diagnosed multiple myeloma treated with the four-drug combination of Sarclisa (isatuximab) ...